Disability-adjusted life years (DALYs) due to the direct health impact of COVID-19 in India, 2020.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Disability-Adjusted Life Years* ; Quality-Adjusted Life Years*; COVID-19/*prevention & control ; Public Health/*statistics & numerical data; Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; COVID-19/virology ; Child ; Female ; Humans ; India/epidemiology ; Male ; Middle Aged ; Pandemics/prevention & control ; Public Health/methods ; Rural Population/statistics & numerical data ; SARS-CoV-2/physiology ; Urban Population/statistics & numerical data ; Young Adult

COVID-19 has affected all countries. Its containment represents a unique challenge for India due to a large population (> 1.38 billion) across a wide range of population densities. Assessment of the COVID-19 disease burden is required to put the disease impact into context and support future pandemic policy development. Here, we present the national-level burden of COVID-19 in India in 2020 that accounts for differences across urban and rural regions and across age groups. Input data were collected from official records or published literature. The proportion of excess COVID-19 deaths was estimated using the Institute for Health Metrics and Evaluation, Washington data. Disability-adjusted life years (DALY) due to COVID-19 were estimated in the Indian population in 2020, comprised of years of life lost (YLL) and years lived with disability (YLD). YLL was estimated by multiplying the number of deaths due to COVID-19 by the residual standard life expectancy at the age of death due to the disease. YLD was calculated as a product of the number of incident cases of COVID-19, disease duration and disability weight. Scenario analyses were conducted to account for excess deaths not recorded in the official data and for reported COVID-19 deaths. The direct impact of COVID-19 in 2020 in India was responsible for 14,100,422 (95% uncertainty interval [UI] 14,030,129-14,213,231) DALYs, consisting of 99.2% (95% UI 98.47-99.64%) YLLs and 0.80% (95% UI 0.36-1.53) YLDs. DALYs were higher in urban (56%; 95% UI 56-57%) than rural areas (44%; 95% UI 43.4-43.6) and in men (64%) than women (36%). In absolute terms, the highest DALYs occurred in the 51-60-year-old age group (28%) but the highest DALYs per 100,000 persons were estimated for the 71-80 years old age group (5481; 95% UI 5464-5500 years). There were 4,815,908 (95% UI 4,760,908-4,924,307) DALYs after considering reported COVID-19 deaths only. The DALY estimations have direct and immediate implications not only for public policy in India, but also internationally given that India represents one sixth of the world's population.
(© 2022. The Author(s).)

BMJ. 2020 Aug 11;370:m3026. (PMID: 32784198)
Lancet Glob Health. 2015 Nov;3(11):e712-23. (PMID: 26475018)
Value Health. 2021 May;24(5):615-624. (PMID: 33933229)
Lancet. 2018 Nov 10;392(10159):1789-1858. (PMID: 30496104)
Int J Environ Res Public Health. 2020 Jun 13;17(12):. (PMID: 32545827)
Int J Public Health. 2021 Mar 05;66:619011. (PMID: 34744580)
BMJ. 2020 Oct 22;371:m3939. (PMID: 33093056)
Indian J Med Res. 2021 Jan & Feb;153(1 & 2):115-125. (PMID: 33818468)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
One Health. 2021 Dec;13:100283. (PMID: 34222606)
PLoS One. 2021 Feb 3;16(2):e0246548. (PMID: 33534870)
Int J Public Health. 2014 Jun;59(3):571-4. (PMID: 24748107)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
Transbound Emerg Dis. 2021 Jul;68(4):2171-2187. (PMID: 33012088)
Science. 2020 Nov 6;370(6517):691-697. (PMID: 33154136)
PLoS Med. 2020 Sep 22;17(9):e1003346. (PMID: 32960881)
Lancet Respir Med. 2020 Jul;8(7):658-659. (PMID: 32473123)
Int J Environ Res Public Health. 2020 Oct 17;17(20):. (PMID: 33080869)
Nat Med. 2020 Apr;26(4):450-452. (PMID: 32284615)
J Infect. 2021 Mar;82(3):378-383. (PMID: 33450302)
Sci Rep. 2021 Feb 18;11(1):3504. (PMID: 33603008)
J Formos Med Assoc. 2021 Jun;120 Suppl 1:S106-S117. (PMID: 34119392)
Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. (PMID: 33444432)
Int J Antimicrob Agents. 2020 Mar;55(3):105924. (PMID: 32081636)
Dtsch Arztebl Int. 2021 Mar 5;118(9):145-151. (PMID: 33958032)
J Korean Med Sci. 2020 Jun 01;35(21):e199. (PMID: 32476305)
Indian J Crit Care Med. 2020 Jul;24(7):509-513. (PMID: 32963432)
Int J Equity Health. 2021 Sep 26;20(1):214. (PMID: 34565406)
Sci Rep. 2021 Jan 26;11(1):2256. (PMID: 33500431)
Int J Public Health. 2014 Jun;59(3):565-9. (PMID: 24752429)
Lancet Infect Dis. 2021 Dec;21(12):1615-1617. (PMID: 34399092)
J Korean Med Sci. 2020 Aug 17;35(32):e300. (PMID: 32808515)
J Public Health (Oxf). 2021 Apr 12;:. (PMID: 33839789)
Nat Commun. 2020 Dec 9;11(1):6317. (PMID: 33298944)
BMJ Open. 2021 Aug 18;11(8):e049619. (PMID: 34408053)
Lancet Infect Dis. 2018 Nov;18(11):1191-1210. (PMID: 30243584)
J Family Med Prim Care. 2020 Oct 05;9(10):5360-5365. (PMID: 33409216)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Lancet Glob Health. 2019 Dec;7(12):e1675-e1684. (PMID: 31708148)
Popul Health Metr. 2015 Apr 03;13:10. (PMID: 26778920)
PLoS One. 2018 Dec 21;13(12):e0209039. (PMID: 30576333)
Indian J Crit Care Med. 2021 Jul;25(7):761-767. (PMID: 34316169)
Nat Med. 2021 Apr;27(4):601-615. (PMID: 33753937)
JAMA Netw Open. 2021 Feb 1;4(2):e210830. (PMID: 33606031)
Lancet. 2020 Oct 17;396(10258):1204-1222. (PMID: 33069326)
Am J Trop Med Hyg. 2021 Jan;104(1):85-90. (PMID: 33205749)
BMJ Open. 2016 Sep 29;6(9):e011699. (PMID: 27687898)

Date Created: 20220215 Date Completed: 20220228 Latest Revision: 20220228

20231215

PMC8844028

10.1038/s41598-022-06505-z

35165362